2. GPCR/G Protein Immunology/Inflammation
  3. CXCR
  4. UCUF-965

UCUF-965 is a CXCR4 positive allosteric modulator. UCUF-965 potentiates CXCL12-induced β-arrestin recruitment and cAMP signaling, activates lymphoblast migration, induces calcium flux, and does not bind CXCR4’s orthosteric CXCL12 site. UCUF-965 reduces miR-15b and miR-29a levels, increases miR-146a levels in fibroblasts. UCUF-965 enhances angiogenesis and reduces wound healing time in diabetic mice. UCUF-965 can be used for the research of diabetic wound healing impairment.

For research use only. We do not sell to patients.

UCUF-965

UCUF-965 Chemical Structure

CAS No. : 2965316-77-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

UCUF-965 Related Antibodies

Top Publications Citing Use of Products

View All CXCR Isoform Specific Products:

View All Isoforms
CXCR CXCR1 CXCR2 CXCR3 CXCR4 CXCR7 CXCR6

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

UCUF-965 is a CXCR4 positive allosteric modulator. UCUF-965 potentiates CXCL12-induced β-arrestin recruitment and cAMP signaling, activates lymphoblast migration, induces calcium flux, and does not bind CXCR4’s orthosteric CXCL12 site. UCUF-965 reduces miR-15b and miR-29a levels, increases miR-146a levels in fibroblasts. UCUF-965 enhances angiogenesis and reduces wound healing time in diabetic mice. UCUF-965 can be used for the research of diabetic wound healing impairment[1].

IC50 & Target[1]

CXCR4

 

In Vitro

UCUF-965 (0.1-10 μM) promotes β-arrestin recruitment with an EC50 of 0.02 μM[1].
UCUF-965 acts as a partial agonist of CXCR4-mediated cAMP inhibition in CXCR4-overexpressing CHO cells, with an EC50 of 0.05 μM[1].
UCUF-965 (0.4 μM; 3 h) induces migration of CEM-CCRF human lymphoblast cells via CXCR4 activation, with an EC50 of 0.4 μM[1].
UCUF-965 (10 μM) induces CXCR4-mediated calcium flux in CEM-CCRF human lymphoblast cells[1].
UCUF-965 (0.1-10 μM; 24 h) modulates the expression of wound healing-related microRNAs in murine diabetic and non-diabetic fibroblasts, reducing miR-15b and miR-29a levels and increasing miR-146a levels[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

UCUF-965 Related Antibodies

Cell Migration Assay [1]

Cell Line: CEM-CCRF human lymphoblast cells
Concentration: 0.4 μM
Incubation Time: 3 h
Result: Induced CEM-CCRF cell migration with an EC50 of 0.4 μM and an average Eₘₐₓ of 31%.

Real Time qPCR[1]

Cell Line: murine diabetic (Db/Db) fibroblasts; murine non-diabetic (HZ) fibroblasts
Concentration: 0.1, 1, 10 μM
Incubation Time: 24 h
Result: Decreased the expression of miR-15b in both diabetic and non-diabetic fibroblasts in a dose-dependent manner.
Decreased miR-29a levels and increased miR-146a levels in both cell types, with responses observed at concentrations as low as 0.1 μM.
In Vivo

UCUF-965 (10 μM; intradermal injection; single dose) reduces diabetic wound healing time by 36% and enhances angiogenesis in diabetic mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Db/Db mice (10-week-old female, diabetic model)[1]
Dosage: 10 μM
Administration: intradermal injection; single dose (immediately after wounding)
Result: Reduced wound surface area compared to controls starting at post-injury day 6.
Achieved full wound closure at day 14, representing a 36% reduction in wound healing time compared to day 22 in PBS-treated controls.
Showed a significant increase in CD31-positive endothelial cells at day 7 post-wounding, reaching levels similar to non-diabetic control wounds.
Molecular Weight

405.52

Formula

C22H23N5OS
CAS No.
SMILES

N=1N=C(C=2C=CC=CC2OCC)N3N=C(C=4C=CC(=CC4)N5CCCC5)CSC13
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

UCUF-965 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

UCUF-9652965316-77-0UCUF965UCUF 965CXCRCXC chemokine receptorsC-X-C motif chemokine receptorsmiR-15bcalcium fluxlymphoblastsβ-arrestinCXCR4cAMP signalingCXCL12miR-29amiR-146adiabetic miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
UCUF-965
Cat. No.:
HY-182850
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.